Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MCRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSeres Therapeutics reports Q1 2026 financial results and operational updates
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the quarter ended March 31, 2026, along with operational updates via press release. Specific figures and details are contained in the attached exhibit.
Item 2.02 verify on EDGAR → -
low
Press release issued May 5, 2026 and furnished as Exhibit 99.1 to the 8-K filing. The filing body itself contains no financial figures or operational details.
Item 9.01 verify on EDGAR →
Summary
Seres Therapeutics filed an 8-K on May 5, 2026 to announce its first quarter 2026 financial results and provide operational updates. The company reported results for the period ending March 31, 2026, though the actual financial figures and operational details are contained in the press release attached as an exhibit rather than in the 8-K body text itself. Retail investors should review the full press release (Exhibit 99.1) to understand the company's Q1 performance, cash position, and any updates on its microbiome therapeutic programs.
As a clinical-stage biotech company, quarterly results typically focus on cash runway, clinical trial progress, and regulatory milestones rather than revenue metrics.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 5, 2026, Seres Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided operational updates.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026, along with operational updates. The actual financial figures and operational details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Seres Therapeutics filed an 8-K attaching a press release issued May 5, 2026; no material business event disclosed in filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Seres Therapeutics, Inc. Press Release issued May 5, 2026
The 8-K discloses that a press release was issued on May 5, 2026 and is attached as Exhibit 99.1. The filing body provides no details about the content or subject matter of the press release, making this a procedural disclosure without material information visible in the 8-K text itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify